To round out the American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium 2023, attendees will learn about different ways of managing renal cell carcinoma (RCC) at all stages from research to practice. Payal Kapur, MD, University of Texas Southwestern Medical Center, will explain the ever-changing pathologic classification of RCC, Steven Campbell, MD, PhD, Cleveland Clinic Glickman Urological and Kidney Institute, will pontificate on improving functional outcomes in localized RCC, and Matthew R Zibelman, MD, Fox Chase Cancer Center, will add context to new data for adjuvant therapies.
Around mid-day, the last general session of the Symposium will occur on multidisciplinary perspectives on challenging RCC cases. In a rapid-fire format, a host of speakers will present on topics such as active surveillance for patients with at-risk disease, managing delayed oligometastatic disease with radiation or surgery, consolidation therapy after immunotherapy with surgery or medical oncology, and the effect of treating residual disease after immunotherapy-based combinations in metastatic disease.
